Lipoprotein (a) [Lp(a)], is one of the most atherogenic lipoproteins, whose significance in health and diseases has been studied for a long time. It was first described in 1963 by a Scandinavian geneticist (Kare Berg) but it took > 20 years to unravel its structure and composition. The role of Lp(a) in cardiovascular disease has become clearer over the last 40 years but a lot of unanswered questions remain. Its physiological function has never been unraveled and Lp(a) lowering therapies are not yet available, even though specific Lp(a) lowering drugs are in late-stage clinical trials.

Today, the important role of Lp(a) in atherogenesis is accepted, despite the fact that many aspects of Lp(a) physiology and pathophysiology are still not fully understood. Because of this and to advance Lp(a) research, this journal was created with a focus on all areas of Lp(a) research, including genetics and genomics, physiology and pathophysiology, epidemiology, translational medicine, clinical and laboratory medicine, therapies and more.

Advances in Lipoprotein(a) Research publishes a limited number of yearly manuscripts of highest quality and aims to be in the forefront of Lipoprotein(a) research. We hope that Advances in Lipoprotein(a) Research inspires and stimulates future Lp(a) research and leads to a better understanding of this important lipoprotein.

We welcome original research article, review, short communication, methods article, perspective, etc.